Pfizer (NYSE:PFE) is preparing multiple presentations for the upcoming ASCO conference that spotlight new data across its ...
Pfizer (NYSE:PFE) reported Phase 2b results for its GLP-1 anti-obesity candidate, PF-08653944, showing potential for a once ...
Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...
Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the ...
Pfizer’s recent positive data for atirmociclib, tilrekimig, Padcev, and the Lyme disease vaccine candidate highlight pipeline ...
Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...
The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...
AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...
The expectation was straightforward: more data would enable faster and better decisions. Instead, many organizations are ...
A 52-week extension study showed that the drug continues to maintain favorable body composition with no safety issues.
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that ...
No increase in subtrochanteric or diaphyseal femur fractures was seen with denosumab use compared with bisphosphonates in 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results